logo

HCM

Hutchmed·NASDAQ
--
--(--)
--
--(--)
4.70 / 10
Netural

Evaluation yields 4.7/10, reflecting fair financial health. Key positives: Interest coverage ratio (EBIT / Interest expense) (%) and Revenue-MV, whereas limitations surface in Total operating revenue (YoY growth rate %) and Operating revenue (YoY growth rate %). This configuration appears balanced.

Fundamental(4.7)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-0.19
Score3/3
Weight20.23%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value-9.16
Score1/3
Weight-1.18%
1M Return-0.79%
Days sales outstanding
Value98.05
Score1/3
Weight-2.22%
1M Return-1.57%
Profit-MV
Value2.09
Score3/3
Weight19.44%
1M Return9.28%
Net income-Revenue
Value2.46
Score3/3
Weight19.19%
1M Return9.29%
PB-ROE
Value0.43
Score1/3
Weight19.64%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight-1.61%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-9.16
Score1/3
Weight-1.14%
1M Return-0.76%
Asset-MV
Value-0.58
Score1/3
Weight11.80%
1M Return6.68%
Cash-MV
Value-0.14
Score2/3
Weight15.86%
1M Return8.41%
Is HCM undervalued or overvalued?
  • HCM scores 4.70/10 on fundamentals and holds a Fair valuation at present. Backed by its 45.18% ROE, 77.64% net margin, 5.67 P/E ratio, 2.13 P/B ratio, and 1180.00% earnings growth, these metrics solidify its Netural investment rating.